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Introduction
Urinary bladder carcinoma ranks the fourth position in
malignancy incidence rates in men (6.1%) and the 17th
position in women (1.6%). In general, neoplastic diseases,
should be approached from two perspectives: prevention
with implementation of prophylactic measures and early
diagnostics. Prophylactics is possible in the preclinical
phase of neoplasm, being both justified and plausible in
patients from high-risk groups. Thus, it is particularly
important to select such groups, not only by referring to
environmental carcinogenic factors (occupational and
extra-occupational) but also from genetic predisposition,
which may be conductive for neoplasm formation. The
mutations / polymorphisms of CHEK2 and CYP1B1
genes predispose to neoplasm via multiorgan mechan-
isms, while the human papilloma virus (HPV) may
actively participate in the neoplastic transformation
towards urinary bladder carcinoma as an environmental
factor.
Goals of study
The primary goal of the study was an evaluation of the
incidence of CHEK2 gene mutations, CYP1B1 polymorph-
ism and of the oncogenic types of HPV in a group of
patients with urinary bladder carcinoma and in control
groups. The secondary goals included a comparison of the
incidence of the above-mentioned mutation/polymorph-
ism and of persistent infection with HPV in the studied
group of patients and in the control group, with a
subsequent determination of the effects, which those
factors could have exerted on the neoplastic process devel-
opment. In general, the studies were undertaken to deter-
mine whether there is any genetic and environmental
predisposition to urothelial carcinoma and to evaluate
possible advantages of the used methods for efficient prog-
nosing of genetic predisposition to urinary bladder carci-
noma development.
Material and methods
The studied group comprised 131 patients with urinary
bladder carcinoma, diagnosed for the first time and
demonstrating various clinical stages (Ta, T1, T2, T3 and
T4) and histological grades of malignancy (G1, G2, G3).
DNA from tumour cells and DNA, isolated from periph-
eral blood, were study materials. The obtained DNA was
then submitted to an intensive search for CHEK2 (IVS2 +
1G>A gene, 1100delC, del5395, I157T) mutation and for
polymorphism of CYP1B1 (355T/T) gene.
In order to find out, whether the searched mutations
occurred somatically (being not limited to neoplastic cells)
or were constitutional in character, the detection was car-
ried out in the DNA from tumour tissue and from periph-
eral blood. The assumed presence of oncogenic types of
HPV was searched in the DNA isolated from tumour
tissue.
The control group included 131 patients (control
group I, II), in whom tests were run for identification of
CHEK2 (IVS2 + 1G>A gene, 1100delC, del5395, I157T)
mutation and of CYP1B1 (355T/T) gene polymorphism
and oncogenic types of HPV in DNA isolated from
epithelial cells in urinary sediment. Seventy-four subjects
from control group III were tested for the presence of
oncogenic HPV in DNA isolated from epithelial cells in
urinary sediment.
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Results
In the study group, a total of 11 mutations of CHEK2 gene
mutations were identified, while 355T/T polymorphism of
CYP1B1 gene was found in 18 cases of the study group
(12.9%). In 36 cases (29.3%), out of 123 examined subjects,
the presence of an oncogenic HPV type was found. In the
control groups (I and II), one I157T missense mutation of
CHEK2 gene was detected. In both control groups, 355T/
T polymorphism of CYP1B1 gene was found in 7 cases.
A study was carried out for the presence of oncogenic
types of the virusin 72 subjects of control group II with
indication to HPV infection diagnostics, demonstrating
the presence of oncogenic HPV in 32 (44.4%) cases.
Seventy-four subjects from control group III with no indi-
cations to tests for the presence of oncogenic HPV, consti-
tuted a reference group. The presence of the virus was
identified in 8 (10.81%) cases.
Conclusions
The performed studies demonstrated a statistically signifi-
cant difference between the study group and the control
group in the incidence of CHEK2 gene mutations, 355T/T
polymorphism of CYP1B1 gene and the presence of onco-
genic HPV types.
Taking into account the obtained results, the following
conclusions have been drawn:
1. CHEK2 gene mutations, 355T/T polymorphism of
CYP1B1 gene and the presence of oncogenic HPV types
are observed with a higher, statistically significant preva-
lence in neoplastic tissue of urinary bladder carcinoma.
2. The concomitance of CHEK2 gene mutations or
355T/T polymorphism of CYP1B1 gene and of the pre-
sence o oncogenic HPV types statistically significantly
correlates with histological malignancy grades of urinary
bladder carcinoma.
3. It seems that occurrence of the mutation of CHEK2
gene, of polymorphism of CYP1B1 gene and of the onco-
genic HPV types can be added to the list of genetic and
environmental factors, predisposing to urinary bladder
carcinoma development and modifying the course of the
disease.
4. Carrying on the above described studies on larger
patient populations can allow in the future on the imple-
mentation conditions for effective prophylactics: at the
carriers of the mutation/polymorphism the elimination/
limitation of the influence of the environmental risk fac-
tors (occupational and/or the smoking of the tobacco),
and early implementation of appropriate antiphlogistic
treatment in this antiviral.
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